Clinicians should monitor liver function in blood cancer patients who are taking ibrutinib (Imbruvica), the TGA has advised. According to information published in the latest Medicines Safety Update therapy should be withheld if ≥ Grade 3 elevations in liver function tests occur – with or without a rise in bilirubin. However once elevations decrease to ...
New safety warning for ibrutinib
12 Apr 2016